Taiwan Liposome Company, Ltd. Initial Public Offering
Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Orchard Therapeutics plc Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…
Gamida Cell Ltd. $50 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…
Kodiak Sciences Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $90 million initial public offering of common stock by Kodiak Sciences Inc. The common stock is listed on the NASDAQ Global Market…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…
Allakos Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of Allakos Inc. at $18.00 per share (which includes the exercise in…
Magenta Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…
Aptinyx Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…
Iterum Therapeutics plc Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…